Health
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information February 26, 2026, 6:30 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the
About this update from Argenx Se
[{"type":"image","alt":"argenx SE","displaySize":"","headline":null,"caption":"argenx SE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_55.hEettGltaZ5cA.9xTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119","width":300,"height":97}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Study met primary endpoint (p-value = 0.012)","length":44,"tagName":"p"}]},{"val":[{"type":"text","content":"First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG ","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG","length":152,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":303,"olType":false},{"type":"text","content":"Regulated Information – Inside Information","length":42,"tagName":"p"},{"type":"text","content":"February 26, 2026, 6:30 AM CET ","length":32,"tagName":"p"},{"type":"text","content":"Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG).","length":370,"tagName":"p"},{"type":"text","content":"ADAPT OCULUS met its primary endpoint (p-value=0.012), showing that patients living with oMG and treated with VYVGART demonstrated statistically significant improvement from baseline in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores at Week 4 compared to placebo. In the overall population, mean change from baseline in patients treated with VYVGART was a 4.04 point improvement in MGII PRO versus a mean change of 1.99 MGII PRO score in patients treated with placebo. Patients treated with VYVGART experienced a marked reduction of key ocular symptoms: diplopia (double vision) and ptosis (drooping of the upper eyelids).","lengt...